Van Hulzen Asset Management LLC Cuts Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Van Hulzen Asset Management LLC has reduced its stake in Gilead Sciences by 28.2%, selling 3,370 shares during Q1, and now holds 8,561 shares valued at $959,000.
• Gilead Sciences reported a Q2 earnings beat with $2.01 EPS, surpassing estimates, and had a revenue of $7.08 billion, up 1.4% year-over-year.
• The company declared a quarterly dividend of $0.79, representing a 2.8% yield, with the ex-dividend date set for September 15th.

Van Hulzen Asset Management LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,561 shares of the biopharmaceutical company's stock after selling 3,370 shares during the quarter. Van Hulzen Asset Management LLC's holdings in Gilead Sciences were worth $959,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its stake in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after buying an additional 2,450 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Gilead Sciences by 5.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,546,721 shares of the biopharmaceutical company's stock valued at $327,612,000 after purchasing an additional 198,528 shares in the last quarter. MGO One Seven LLC grew its holdings in shares of Gilead Sciences by 70.8% in the fourth quarter. MGO One Seven LLC now owns 11,195 shares of the biopharmaceutical company's stock valued at $1,034,000 after purchasing an additional 4,639 shares in the last quarter. Integrated Wealth Concepts LLC increased its position in Gilead Sciences by 4.7% in the fourth quarter. Integrated Wealth Concepts LLC now owns 26,687 shares of the biopharmaceutical company's stock worth $2,465,000 after purchasing an additional 1,194 shares during the last quarter. Finally, Nebula Research & Development LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at $288,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $114.77 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $142.41 billion, a P/E ratio of 22.86, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33. Gilead Sciences, Inc. has a 1-year low of $75.91 and a 1-year high of $121.83. The company's 50-day moving average is $112.51 and its 200 day moving average is $109.02.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the business earned $2.01 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares in the company, valued at approximately $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,000 shares of company stock worth $9,339,230. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a report on Tuesday. Royal Bank Of Canada lifted their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Oppenheimer reduced their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Finally, Morgan Stanley raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.